Medical/Pharmaceuticals

How latest genetic data on fertility may be an indicator of chronic disease onset and longevity

SINGAPORE, May 2, 2025 /PRNewswire/ -- Latest population studies have cast new light on genetic influences on women's reproductive lifespans and possible markers for the onset of chronic diseases. Evidence is growing that conditions such as cardiovascular disease, type 2 diabetes, rheumatoid a...

2025-05-02 15:59 3801

AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.

AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficac...

2025-05-02 10:42 3016

HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion

SINGAPORE, May 2, 2025 /PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S$9 million inves...

2025-05-02 10:00 2877

Fertility experts urge the creation of registries to safeguard donor conception practices

SINGAPORE, May 2, 2025 /PRNewswire/ -- Gamete donation has accelerated around the world in the past decade driven in part by the emergence of commercial sperm and egg banks and a growing recognition of the validity of this form of family buildingamong single women in some countries. However, l...

2025-05-02 09:51 2608

VISTA Eye Specialist Celebrates Breakthrough PX Ninety Collaboration with Shareef Mahdavi—Now Featured in Leading U.S. Medical Journal

PETALING JAYA, Malaysia, May 2, 2025 /PRNewswire/ -- Just months after announcing its dynamic partnership with world-renowned patient experience expert Shareef Mahdavi and the PX Ninety program,VISTA Eye Specialist is thrilled to mark a major milestone: the story of its PX Ninety and Ikigai WowX ...

2025-05-02 08:00 2728

FaceHeart Received Another FDA Clearance for its Contactless Video-Based Vital Sign Measurement of Respiratory Rate

* Developed by FaceHeart, FH Vitals SDK-RR has obtained FDA Clearance. This is the second 510(k) class II SaMD (Software as a Medical Device) FaceHeart received from the FDA. * FaceHeart Vitals™ is a video-based, contactless vital sign measurement SDK that can be integrated into devices such ...

2025-05-01 23:06 2826

A global study led by CUHK and the University of Calgary charts four-stage evolution of Inflammatory Bowel Disease

HONG KONG, May 1, 2025 /PRNewswire/ -- An international consortium led by The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and the University of Calgary in Canada has conducted a global epidemiological study on Inflammatory Bowel Disease (IBD). It found that this chr...

2025-05-01 15:05 2970

A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis

SUZHOU, China, May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemother...

2025-05-01 09:49 2961

Preserving fertility and optimising care for the one in seven women suffering from endometriosis

SINGAPORE, May 1, 2025 /PRNewswire/ -- Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to help preserve the fertility of those with the debilitating condition. They have finalised a rigorous co...

2025-05-01 08:29 2532

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd. , a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investiga...

2025-05-01 08:00 2711

Natus announces integration of InVisus Pro NMUS into Natus Elite software

MIDDLETON, Wis., May 1, 2025 /PRNewswire/ -- Natus Medical Incorporated has announced its InVisus Pro Neuromuscular Ultrasound system can now be seamlessly integrated with all Natus EMG systems via Natus Elite Software, providing users of the portable, stand-alone neuromuscular ultrasound with th...

2025-05-01 03:15 2720

JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection

SHANGHAI, April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital ofSichuan University, recently announced the successful completion of first-in-human ("FIH") feasibility study of its innovative, proprie...

2025-04-30 21:00 1985

ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care

Showcasing the future of ophthalmic research at ARVO 2025: * ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows. * ZEISS's collaboration with Boehring...

2025-04-30 21:00 2327

Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting

SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster format at the American Association for Cancer Research (AACR) annual meeting, held from Ap...

2025-04-30 20:00 2281

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

PRAGUE and BUDAPEST, Hungary, April 30, 2025 /PRNewswire/ -- Modern medical treatment options for endometriosis were among the main topics at the SEUD Congress  (Society of Endometriosis and Uterine Disorders) held in Prague between 24-26 April, where a highly successful sympos...

2025-04-30 19:00 2151

Genocury Biotech Annouces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy

Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability. Results are attained without requiring lymphodepletion. SHENZHEN, China, April 30, 2025 /PRNewswire/ -- Genocury Biotech today revealed groundbreaking clinic...

2025-04-30 15:11 1916

AXA Enhances GBA Medical Concierge Service Network

Launches First-Ever Northbound and Southbound Cancer Care Available to Both Individual and Group Customers HONG KONG, April 30, 2025 /PRNewswire/ -- AXA Hong Kong and Macau ("AXA") today announced a comprehensive upgrade to its GBA Medical Concierge Service Network. This enhancement includes an ...

2025-04-30 13:48 2540

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025

SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings for the next-generation EGFR-TKI therapeutic 'JIN-A02' (clinical Phase 1/2 results) and the ovarian cancer treatment candidate 'JIN-001' (preclinic...

2025-04-30 13:03 2361

Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting

SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meetin...

2025-04-30 10:35 2690

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2025-04-30 08:00 2791
1 ... 92939495969798 ... 645

Week's Top Stories